The Power of Pills

'An impressive collection of essays focusing on one of the most pressing issues of our time. The Power of Pills provides the resources for a debate we urgently need to have' -- Professor Peter Singer, Princeton University 'This concise, incisive book offers a comprehensive, timely review of ethical, legal, social, and trade concerns in pharmaceutical industry dynamics' -- Professor Bernard M. Dickens, University of Toronto

Jillian Clare Cohen is an Assistant Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto and Director of the Comparative Program on Health and Society. She is the co-editor of The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing (Pluto, 2006). Patricia Illingworth is an Associate Professor at Northeastern University. She is the co-editor of The Power of Pills (Pluto, 2006), and the author of Trusting Medicine (2005), and Ethical Health Care (2006). Udo Schuklenk is a Professor of Ethics in Public Policy and Corporate Governance at Glasgow Caledonian University. He is a co-editor of The Power of Pills (Pluto, 2006).

Part 1: Pharmaceutical Industry, Profits and Obligations 1. The Pharmaceutical Industry and the Pursuit of Profits by Joel Lexchin 2. Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing Policies: 'Setting Priorities: Pharmaceuticals as Private Organizations and the Duty to Make Money/Maximize Profits' by Kristina M. Lybecker 3. The Pharmaceutical Industry and its Obligations in the Developing World by Ann Mills, Patricia Werhane, and Michael Gorman 4. Drug Companies as Organizational Hybrids by Warren Kaplan 5. Physicians and the Pharmaceutical Industry: A Symbiotic Relationship? by Ian E Marshall 6. Industry Perspectives on Equity, Access and Corporate Social Responsibility: A View from the Inside by Robert A Freeman Part 2: Justice - Medicines as Global Public Goods 1. Pharmaceuticals, Public Health and the Law: A Public Health Perspective by W.E. Parmet 2. Access to Medications and Global Justice by David. Resnik 3. Pharmacogenetics and Global (In)Justice by Soren Holm Part 3: The Social, Ethical and Political Challenge: Neglected Diseases 1. The Enduring Crisis in Neglected Diseases by Nathan Ford 2. Moving Beyond Charity for R&D for Neglected Diseases by J. Orbinski and B. Burciul 3. Neglected Disease Research: Health Needs and New Models for R&D by Aidan Hollis 4. Advance Purchase Commitments: Moral and Practical Problems by Donald W. Light 5. Harnessing the Power of Pharmaceutical Innovation by Thomas Pogge Part 4: Patents and Access to Medicines 1. Patents, Profits, and the Price of Pills: Implications for Access and Availability by Michael J Selgelid and Eline M. Sepers 2. Fair Followers Expanding Access to Generic Pharmaceuticals for Low-Income Populations by Kevin Outterson 3. Abolishing the Product Patent: A Step Forward for Global Access to Drugs by Adam Mannan and Alan Story 4. Trading Health for Profit: Bilateral and Regional Free Trade Agreements Affecting Domestic Intellectual Property Rules on Pharmaceuticals by Lisa Forman Part 5: Research Ethics a 1. Human Genomic Research Ethics: Changing the Rules by Steven H. Miles 2. Assumptions in the Standard of Care Debate by Florencia Luna Part 6: Political Activism and Treatment Access 1. Medicines for All? Commitment and Compromise in the Fight for Canada's Law on Compulsory Licensing for Export by Richard Elliot 2. Placing Access to Essential Medicine on the Human Rights Agenda by Brook K. Baker Part 7: National Responsibilities 1. Producing Affordable Medicines in South Africa by Joao L. Carapinha 2. National Responsibility in the Provision of Basic Medicine by Kinsley Wilson, Laura Esmail and Jillian Clare Cohen 3. Pharmaceutical Cost-Effectiveness Pricing: Developing and Protecting a Global Ideal Form by Thomas A. Faunce Index